FDA advisers in March voted 9-0 that tofersen’s effect on neurofilament, an emerging ALS biomarker, could be a reasonable predictor of clinical benefit.
FDA advisers in March voted 9-0 that tofersen’s effect on neurofilament, an emerging ALS biomarker, could be a reasonable predictor of clinical benefit.